Moderna, Inc. (MRNA) Total liabilities 2017–2025
Moderna, Inc. (MRNA) total liabilities at each fiscal year-end, per SEC filings.
$3.7BFY2025 · since FY2017: $459.2M → $3.7B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.7B | +13.8% |
| FY2024 | $3.2B | -29.1% |
| FY2023 | $4.6B | -32.1% |
| FY2022 | $6.7B | -36.0% |
| FY2021 | $10.5B | +120.4% |
| FY2020 | $4.8B | +1051.9% |
| FY2019 | $414.6M | -4.0% |
| FY2018 | $431.9M | -5.9% |
| FY2017 | $459.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MRNA financial trends
MRNA RevenueMRNA Net incomeMRNA Net marginMRNA Gross profitMRNA Gross marginMRNA Operating incomeMRNA Operating marginMRNA Operating cash flowMRNA Free cash flowMRNA Capital expendituresMRNA Return on equityMRNA Stock buybacksMRNA Dividends paidMRNA Total assetsMRNA Shareholders’ equityMRNA overview →